تصفح حسب الناشر

السجلات المعروضة 1 -- 9 من 9

    • Covid-19 Vaccine Protection among Children and Adolescents in Qatar. 

      Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...

    • Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...

    • Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Butt, Adeel A ( Massachusetts Medical Society , 2021 , Other)
      The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, ...

    • Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. 

      Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

    • Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...

    • Protection against Reinfection with the Omicron BA.2.75 Subvariant 

      Chemaitelly, Hiam; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al-Khatib, Hebah A.; ... more authors ( Massachusetts Medical Society , 2023 , Other)
      The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ...

    • Protection against the omicron variant from previous SARS-CoV-2 infection 

      Altarawneh, Heba N.; Chemaitelly, Hiam; Hasan, Mohammad R.; Ayoub, Houssein H.; Qassim, Suelen; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...

    • Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. 

      Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Hasan, Mohammad R; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The BA.4 and BA.5 subvariants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant have shown the capacity of escaping from neutralizing antibodies.1 These subvariants had an ...

    • Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. 

      Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2021 , Article)
      Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...